Fisher Asset Management LLC Sells 529 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Fisher Asset Management LLC reduced its position in iShares Biotechnology ETF (NASDAQ:IBB) by 19.9% during the third quarter, Holdings Channel.com reports. The firm owned 2,134 shares of the financial services provider’s stock after selling 529 shares during the quarter. Fisher Asset Management LLC’s holdings in iShares Biotechnology ETF were worth $311,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of IBB. Darwin Wealth Management LLC acquired a new position in iShares Biotechnology ETF during the third quarter worth $29,000. Highline Wealth Partners LLC bought a new position in iShares Biotechnology ETF in the 3rd quarter valued at about $30,000. Bbjs Financial Advisors LLC bought a new position in shares of iShares Biotechnology ETF in the second quarter valued at approximately $31,000. Ashton Thomas Securities LLC purchased a new position in shares of iShares Biotechnology ETF during the third quarter valued at approximately $36,000. Finally, Voisard Asset Management Group Inc. bought a new stake in iShares Biotechnology ETF during the third quarter worth $59,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

NASDAQ IBB opened at $141.55 on Monday. The business has a fifty day simple moving average of $142.71 and a 200 day simple moving average of $142.06. iShares Biotechnology ETF has a 12 month low of $119.95 and a 12 month high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The company also recently declared a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were issued a dividend of $0.2005 per share. The ex-dividend date was Wednesday, September 25th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.